CA-JUMPCODE-GENOMICS
13.6.2024 08:01:34 CEST | Business Wire | Press release
Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, and Takara Bio USA, Inc. (“Takara Bio USA”), a wholly owned subsidiary of Takara Bio Inc., today announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.
Under the terms of the agreement Jumpcode and Takara Bio USA have each granted the other party a license to use their IP in exchange for an agreed royalty payment. The financial terms were not disclosed. The companies’ combined IP comprises multiple patents and patent applications worldwide, including U.S. Patent 11,708,606, held by Jumpcode, and U.S. Patent 10,150,985, held by Takara Bio USA.
The companies’ cutting-edge technologies, sold under the DepleteX® and CRISPRclean brands by Jumpcode and as ZapR technology by Takara Bio USA, remove unwanted sequences from biological samples to enable the discovery and detection of novel molecules. This enables researchers to significantly improve the sensitivity of their RNA-seq libraries and provides significant cost savings by reducing the need to sequence unwanted abundant sequences.
The technology can be used in multiple research and translational applications and has the potential to be utilized to rapidly detect unknown, previously undetectable pathogens, which is critically important, particularly in the event of a future pandemic.
Commenting on the partnership Mike Salter, President and CEO of Jumpcode, said: “We are delighted to partner with Takara. Our combined technology is instrumental to scientists around the world enabling them to deliver groundbreaking research, and we are excited by its potential to transform the future of molecular biology. We look forward to working with Takara Bio USA as we focus on the global commercialisation of our products.”
Carol Lou, President & CEO of Takara Bio USA, said: “We are very pleased to be working with Jumpcode to bring together the innovative technology platforms and foundational IP of both companies. This agreement brings clarity for both Takara Bio USA’s and Jumpcode’s customers and partners and paves the way for both companies to combine their strengths to better enable genomics research.”
About Jumpcode Genomics
Jumpcode Genomics is changing genomics with technology that enables critical workflows for research and clinical applications to break through existing barriers. Our CRISPR-based technology removes uninformative sequences allowing for the sensitive detection of biologically relevant molecules. Combining this technology and next-generation sequencing, it’s now possible to search for and discover novel signals that were previously undetectable for greater insights and broadening the understanding of human biology. Discover what we can do at www.jumpcodegenomics.com. Follow Jumpcode on LinkedIn and Twitter @JumpcodeG.
About Takara Bio
Takara Bio USA, Inc. is a wholly owned subsidiary of Takara Bio Inc. that manufactured and distributes kits, reagents and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification and automated sample preparation.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin® reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612041634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ministerial Roundtable Discusses Mobilising Green Investments for a Resilient and Inclusive Global Economy22.10.2026 16:49:00 CEST | Press release
HE Saeed Mohammed Al Tayer, Chairman of the World Green Economy Organization, opened the Ministerial Roundtable titled "From Ambition to Bankable Action-Mobilising Green Investments for a Resilient and Inclusive Global Economy," during the 12th World Green Economy Summit (WGES), held on 21-22 October 2026 at the Dubai World Trade Centre under the theme "From Success to Scale: Showcasing the Green Economy." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022803264/en/ Ministerial Roundtable Discusses Mobilising Green Investments for a Resilient and Inclusive Global Economy (Photo: AETOSWire) The session was attended by HE Dr. Amna bint Abdullah Al Dahak, Minister of Climate Change and Environment, the United Arab Emirates; HE Aliou Gori Diouf, Minister of Environment and Ecological Transition, Senegal; HE Balarabe Abbas Lawal, Minister of Environment, Nigeria; HE Steven Victor, Minister of Agriculture, Fisheries, and the En
SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age22.10.2026 15:00:00 CEST | Press release
Leveraging the Waqoo Group’s research and technology ecosystem to establish a new personal baseline for proactive health and longevity SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022474590/en/ SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age Development will be led by the Company’s AI and longevity-focused subsidiary, SBC AI Longevity Innovation, Inc. The initiative will leverage the regenerative medicine research and technology base established by Waqoo, Inc. (TOKYO: 4937), a consolidated subsidiary of SBC Medical, and its subsidiary Cel
Lenovo Expands AI Library with Proven, Validated Use Cases to Accelerate Business Outcomes and Drive Greater Value Per Token22.10.2026 15:00:00 CEST | Press release
New enterprise AI use cases and research findings show how organizations can move from AI experimentation to measurable value up to 24x faster1 while improving the economics of AISignal65 analysis shows how enterprise customers can lower cost per token by up to 70% at full utilization with on-premises Lenovo Hybrid AI Factories compared to hyperscale API pricing4 Lenovo today expanded the Lenovo AI Library with new, validated AI use cases, extending its portfolio of enterprise-ready solutions that can help organizations move from AI experimentation to measurable business outcomes up to 24x faster1 than custom-built implementations. Now available through the Lenovo AI Library, the added use cases provide proven starting points to accelerate AI deployments and realize returns from investments sooner. Alongside the expansion, new research conducted by The Futurum Group and Signal65 validates how Lenovo’s AI Library, infrastructure and services can help enterprises optimize AI economics fo
Follow-on Order Brings Orders from INNIO Data Center Customer to 1.72 GW, Further Strengthening INNIO’s Data Center Backlog and Revenue Visibility22.10.2026 14:30:00 CEST | Press release
Customer also signs long-term full maintenance agreement for first 500 MW, expanding INNIO’s recurring services base. INNIO N.V. (Nasdaq: INIO) today announced a 620 megawatt (MW) follow-on order from a leading developer and operator of mega-scale data center campuses in the U.S. Together with the customer’s 1.1 gigawatt (GW) order announced in July 2026, the new order brings cumulative orders from the customer to approximately 1.72 GW, further strengthening INNIO’s order backlog and visibility into future revenues. “This follow-on order, coming just months after the customer’s initial 1.1 GW order, underscores the strength of customer demand and continued confidence in INNIO. Our containerized Jenbacher solutions deliver what data centers need most: fast deployment, high power density, fuel efficiency, and the performance to support demanding AI workloads,” said Dr. Olaf Berlien, President and CEO of INNIO. “Repeat orders of this scale, combined with long-term service agreements, stre
European Public Transport Budgets Require 36% Annual Spending Increase by 2035, Arthur D. Little and Polis Research Finds22.10.2026 14:30:00 CEST | Press release
Europe’s public transport sector currently accounts for €130 billion in annual expenditure, yet faces a growing funding gap as demand rises and environmental and resilience requirements intensify. New research from Arthur D. Little (ADL)’s Future of Mobility Lab and POLIS, a network of European cities and regions collaborating to develop innovative and sustainable urban transport solutions, outlines the scale of this financial shortfall and provides radical recommendations for overcoming it. Based on research with senior transport and policymakers, in-depth literature reviews, and real-world data from Paris, London, Amsterdam, Berlin and New York, the report estimates that additional spending will require a 36% increase in overall annual expenditure from now to 2035 onwards. This is made up of a 13% rise in operating expenditure (OPEX) and 56% in capital expenditure (CAPEX), driven by: Hidden debt caused by historic underinvestment in existing infrastructure (6% of additional funding n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom